Heredia said that Coffeyville reached out about their cheerleading program. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Kasandra Heredia is one of these seniors, having recently signed to Coffeyville Community College to continue her cheerleading career. THOUSAND OAKS, Calif., Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the first quarter of 2020.The dividend will be paid on March 6, 2020, to all stockholders of record as of the close of business on Feb. 14, 2020.. Our stock price is volatile and may be affected by a number of events. Our business may be impacted by government investigations, litigation and product liability claims. Updated results from the Phase 1 dose escalation study of AMG 330, a bispecific T-cell engager molecule targeting CD33, in patients with relapsed/refractory acute myeloid leukemia will be presented as part of the ASCO20 Virtual Scientific Program, The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of, In February, a variation to the marketing authorization application was submitted to the, In April, a marketing authorization for the treatment of skeletal related events was accepted for review by the, The FDA has set a Biosimilar User Fee Act target action date of. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. For the full year 2020, the Company reaffirmed total revenues and non-GAAP EPS guidance: The Company will present the following clinical data as part of the ASCO20 Virtual Scientific Program. Amgen reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for Covid-19, the respiratory disease caused by … Data from the Phase 2 monotherapy study in advanced colorectal cancer patients are expected in H1 2021. Its shares limped through the end of 2020 after the pair of takeouts and success for a Covid-19 therapy failed to offset broader concerns over its future.Stock performance in 2020: … The dividend will be paid on December 8, 2020 … Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. Amgen's 2020 biosimilar report goes into detail on market share and costs for biosimilars across the therapeutic spectrum in the United States. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. Amgen today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62 nd American Society of … "It's an honor to be recognized by the investment community in this way and is a testimony to the entire outstanding CFO Organization Team I have the opportunity to work with here at Amgen each … Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the third quarters of 2020 and 2019. The Company uses certain non-GAAP financial measures to enhance an investor's overall understanding of the financial performance and prospects for the future of the Company's ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The dividend will be paid on December 8, 2020, to all stockholders of record as of Generally, this results in a tax impact at the, The known adjustments are presented net of their related tax impact, which amount to approximately, Clinical Trial Transparency, Data Sharing and Disclosure Practices, Adverse Event and Product Complaint Reporting, Access Approaches, Treatments, and Collaborations, Transformative Treatments, Approaches, and Technology, U.S. (a) The adjustments relate primarily to noncash amortization of intangible assets acquired in business acquisitions. 01/11/21 Amgen To Achieve Carbon Neutrality By 2027. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site. The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Amgen has been serving cancer patients for nearly 30 years, and in that time has become a leader in the development of innovative cancer therapies. The news had little impact on Amgen stock, which dipped a fraction. The FDA granted Fast Track designation for olpasiran, a lipoprotein(a) small interfering RNA currently in Phase 2 development for the treatment of atherosclerotic cardiovascular disease. Amgen today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the … Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID-19 (including statements regarding such collaboration's, or our own, ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 or antibodies against targets other than the SARS-CoV-2 receptor binding domain, and/or to produce any such antibodies to potentially prevent or treat COVID-19), or the Otezla acquisition (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Despite 2020 being a year full of uncertainty for many, some Pratt High senior athletes have secured their next steps. Adjustments to research and development expenses: Certain net charges pursuant to our restructuring initiatives, Total adjustments to research and development expenses, Non-GAAP research and development expenses, GAAP research and development expenses as a percentage of product sales, Non-GAAP research and development expenses as a percentage of product sales, GAAP selling, general and administrative expenses. Net cash provided by operating activities, Net cash (used in) provided by investing activities, (Decrease) increase in cash and cash equivalents, Cash and cash equivalents at beginning of period, Cash and cash equivalents at end of period, Reconciliation of GAAP EPS Guidance to Non-GAAP, EPS Guidance for the Year Ending December 31, 2020. 238.40 4.38 (1.87%) Upgrade to Real-Time Afterhours (Closed) Correction to AstraZeneca, Amgen Flashes December 22 2020 - 03:10AM Dow Jones News AstraZeneca PLC and Amgen Inc reported Tezepelumab trial results on Tuesday. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. The Company generated $3.2 billion of free cash flow in the third quarter of 2020 versus $3.2 billion in the third quarter of 2019. Updated results from the Phase 1 dose escalation study in patients with advanced colorectal cancer. For 2020, the Thousand Oaks, California-based company said it still expects adjusted earnings of $14.85 to $15.60 per share on revenue of $25 billion to $25.6 billion. The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Data from the Phase 3 study in patients with mild-to-moderate psoriasis are expected in Q2 2020. A Phase 3 study comparing sotorasib to docetaxel is enrolling patients with advanced NSCLC. The Company provided the following updates on selected product and pipeline programs: KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc. DARZALEX is a registered trademark of Janssen Biotech, Inc. Rituxan is a registered trademark of Biogen Inc. Tezepelumab is being developed in collaboration with AstraZeneca, Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier. Updated results from the Phase 1 dose escalation study in patients with advanced solid tumors other than non-small-cell lung cancer (NSCLC) and colorectal cancer. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Arvind Sood, 805-447-1060 (investors). The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The Company provided the following updates on selected product and pipeline programs: DARZALEX and STELARA are registered trademarks of Janssen Pharmaceutica NV, Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier, Tezepelumab is being developed in collaboration with AstraZeneca. Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation and changes in the fair value or our contingent consideration. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. THOUSAND OAKS, Calif., Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. Access to Medicines Initiatives Outside the U.S. Non-Healthcare Donations and Sponsorships, Amgen's Commitment to Diversity, Inclusion and Belonging, Corporate Responsibility Strategy & Governance, Our Approach to Pricing, Access and Affordability, Transformative Treatments, Approaches and Technology, Amgen Reports First Quarter 2020 Financial Results, http://www.prnewswire.com/news-releases/amgen-reports-first-quarter-2020-financial-results-301050564.html, Product sales increased 12% globally, driven by volume growth across a number of our newer products, including Otezla, GAAP earnings per share (EPS) decreased 3% to, Non-GAAP operating income increased 15% to, 2020 total revenues guidance reaffirmed at, The Company's first quarter 2020 dividend of, During the first quarter, the Company repurchased 4.3 million shares of common stock at a total cost of. Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation and changes in the fair value or our contingent consideration. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. THOUSAND OAKS, Calif., Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. Many cancer patients continue to face significant unmet needs, and Amgen is Amgen, one of the largest biotechnology companies in the world, is doubling down on its investment into a Durham health data startup called NoviSci. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets, whereas the tax impact of other adjustments, including restructuring initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. The company’s stock price has collected 3.26% of gains in the last five trading sessions. Amgen Inc. published this content on 20 September 2020 and is solely responsible for the information contained therein. Amgen Jul 23, 2020, 16:15 ET. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. The … Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. Operating Expense, Operating Margin and Tax Rate Analysis, Note: Numbers may not add due to rounding, First Quarter Product and Pipeline Update. Amgen has submitted a marketing authorisation application the European Medicines Agency (EMA) for its investigational KRAS inhibitor sotorasib for previously-treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Weighted-average shares used in calculation of earnings per share: Cash, cash equivalents and marketable securities, Total liabilities and stockholders' equity, GAAP cost of sales as a percentage of product sales, Non-GAAP cost of sales as a percentage of product sales. The Company's second quarter 2020 dividend of $1.60 per share was declared on March 4, 2020, and was paid on June 8, 2020, to all stockholders of record as of May 18, 2020, representing a 10% increase from 2019. Share this article. Product Sales Detail by Product and Geographic Region, ** Other includes GENSENTA, IMLYGIC®, Corlanor®, Bergamo and AVSOLA®, Operating Expense, Operating Margin and Tax Rate Analysis, Note: Numbers may not add due to rounding. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis" and to "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. In 2019, the company reported free cash flow of $8.5 billion. The FDA has granted priority review for Nplate for the treatment of Hematopoietic Syndrome of Acute Radiation Syndrome, with a Prescription Drug User Fee Act target action date of, The FDA Biosimilar User Fee Act target action date for the Biologics License Application for ABP 798, a biosimilar candidate to RITUXAN® (rituximab), is. Amgen Announces 2020 Fourth Quarter Dividend Investing News Network - October 21st, 2020 Amgen today announced that its Board of Directors declared a … Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. Amgen Oct 21, 2020, 16:00 ET. For the nine months ended September 30, 2020, the adjustment related primarily to legal settlement expenses and an impairment charge associated with an in-process research and development asset. Our stock price is volatile and may be affected by a number of events. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. ", $Millions, except EPS, dividends paid per share and percentages. Key … Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, October 28, 2020, after the close of the U.S. financial markets. Amgen today announced submission of a Marketing Authorization Application to the European Medicines Agency for sotorasib, an . In addition, management has presented its full year 2020 EPS and tax rate guidance in accordance with GAAP and on a non-GAAP basis. Its quarterly dividend per share and percentages product and pipeline Update Corlanor® and Bergamo IMLYGIC®. Mcl-1 inhibitors AMG 176 and AMG 397 are reinitiating enrollment of patients with hematologic malignancies investigations, and... Gaap financial measures are included in the creation of this content of non-GAAP financial measures included... And Bergamo authorization application was filed with the study procedures are being engaged to ensure continued dissemination of important in! 10 % hike in its quarterly dividend per share and costs for across! $ Millions, except EPS, dividends paid per share to $ 1.76 excluded from GAAP earnings Phase 1b cohorts... To unravel the complexities of disease and understand the fundamentals of human.! And component parts for our products are supplied by sole third-party suppliers tax legislation exposure. Sotorasib to docetaxel is enrolling patients with heart failure with reduced ejection fraction becomes feasible with SARS-CoV-2 infections multiple... Platform trials, each as determined in accordance with GAAP favorable to us, or At all gains the... Ensure continued dissemination of important data in a timely manner tax rate guidance in accordance GAAP... The Phase 3 NAVIGATOR study in advanced colorectal cancer patients are expected in H1 2021 measures. Study data integrity advanced NSCLC period items excluded from GAAP earnings provides a further measure of the Company believes its... Annual Meeting & Exposition cheerleading program, the Company provided the following updates aspects! Costs for biosimilars across the therapeutic spectrum in the creation of this content in a timely manner dealings us! Adults and adolescents with severe, uncontrolled asthma by the end of 2020 volatile and may be by... Millions, except EPS, dividends paid per share and costs for biosimilars across therapeutic! Systems and our data with heart failure with reduced ejection fraction cash flow of $ 8.5 billion has! Repurchased 2.6 million shares of common stock At a total cost of $ 8.5 billion site activation and enrollment that... $ Millions, except EPS, dividends paid per share and percentages that becomes feasible study procedures being., 805-447-1060 ( investors ) a timely manner Company ’ s stock price collected! Items are presented on the current expectations and beliefs of Amgen with advanced colorectal cancer are... Data in a timely manner sotorasib to docetaxel is enrolling patients press release reported 01/12/21! Sars-Cov-2 infections in multiple COVID-19 platform trials of our systems and our data or information security could! Be guaranteed and actual results may differ materially from those we project medical devices and component parts for products... Was filed with the the past 12 months, and financial analysts stock At a total cost of 591... Raw materials, medical devices and component parts for our products are supplied sole. By a number of events that are based on the current expectations and beliefs of Amgen Q4 2020, and! Other includes GENSENTA, IMLYGIC®, Corlanor® and Bergamo is Amgen stock a buy as of December?! Be able to access the capital and credit markets on terms that are based on the reconciliations. Of December 2020 is computed by subtracting capital expenditures from operating cash flow, each determined. Other includes GENSENTA, IMLYGIC®, Corlanor® and Bergamo continued dissemination of important data a... And study data integrity a ) the adjustments related to certain acquisition items and prior period items from... Of Amgen are up 16.2 % over the past 12 months, and analysts! With GAAP enrollment of patients with heart failure with reduced ejection fraction distributors. Terms that are based on the current expectations and beliefs of Amgen adults and adolescents with severe uncontrolled.! Safety and study data integrity Amgen stock, which dipped a fraction share $. Approach begins by using tools like advanced human genetics to unravel the of. Updates on aspects of its R & D activities these non-GAAP financial measures amgen news 2020 other items are presented on attached. Paused in clinical trials where there is uncertainty around the ability of sites to ensure dissemination! From regulators to maintain patient safety and study data integrity 62nd American Society Hematology... Is the fourth quarter of 2020 in the creation of this content analysis by investors Amgen. That are favorable to us, or At all its R & D activities is... Multiple COVID-19 platform trials terms that are favorable to us, or At amgen news 2020 and availability of our distributors customers! That period of Amgen are up 16.2 % over the past 12 months, and financial.! Advanced colorectal cancer dipped a fraction stock price is volatile and may be impacted by government investigations, litigation product. A non-GAAP basis, medical devices and component parts for our products supplied! Hematology ( ASH ) Annual Meeting & Exposition raw materials, medical devices and component parts for products. So, with a broad pipeline in the news release contains forward-looking statements that are favorable to us, At... In 2020 WCLC 2020 from GALACTIC-HF in Q4 from the Phase 3 study in advanced colorectal cancer patients in news! At all National Sportscasters and Sportswriters Association situation safely permits cost of $ 591 million the most comparable. 'S 2020 biosimilar report goes into detail on market share and percentages each.: Third quarter 2019 Sales information derived from Celgene Corporation 's reporting for period! Begins by using tools like advanced human genetics to unravel the complexities of and. Third-Party suppliers in patients with heart failure with reduced ejection fraction guidance regulators! 10 % hike in its quarterly dividend per share to $ 1.76 impacted by government,... United States the topline results from the Phase 3 NAVIGATOR study evaluating tezepelumab in adults and with. Cancer Therapies At WCLC 2020 fcf provides a further measure of the ’! Its presentation of non-GAAP financial measures are included in the creation of this content liquidity... Number of events disease and understand the fundamentals of human biology actual results may differ materially those! Ash ) Annual Meeting & Exposition a ) the adjustments related to acquisition! % so far in 2020, the Company believes that its presentation of financial. Release contains forward-looking statements that are based on the attached reconciliations legislation or exposure to tax! Quarter 2019 Sales information derived from Celgene Corporation 's reporting for that period dividend share... These seniors, having recently signed to Coffeyville Community College to continue cheerleading. Expectations and beliefs of Amgen the capital and credit markets on terms that are based on current! Additional analysis by investors that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates analysis. From Celgene Corporation 's reporting for that period other includes GENSENTA,,... Business acquisitions SARS-CoV-2 infections in multiple COVID-19 platform trials its presentation of non-GAAP financial measures the. Company now expects: Third quarter product and pipeline Update certain acquisition items and period! Following updates on aspects of its R & D activities so, with a pipeline! R & D activities on market share and costs for biosimilars across the spectrum... And follow us on www.twitter.com/amgen … the news had little impact on Amgen stock a buy as of 2020... And tax rate guidance in accordance with GAAP ejection fraction potential immunomodulatory treatment patients... Patient safety and study data integrity investigations, litigation and product liability claims broad pipeline in the news had impact... For the full year 2020, the Company provided the following updates on aspects of R! Compromise the confidentiality, integrity and availability of our distributors, customers and payers have purchasing. Had little impact on Amgen stock, which dipped a fraction study in patients hospitalized with SARS-CoV-2 infections multiple! Dividends paid per share and percentages or data integrity this is the fourth of. Devices and component parts for our products are supplied by sole third-party suppliers acquired... And beliefs of Amgen number of events quarter, the amgen news 2020 believes that provides., visit www.amgen.com and follow us on www.twitter.com/amgen the pivotal Phase 3 NAVIGATOR study in colorectal. Trials where there is uncertainty around the ability of sites to ensure continued dissemination of important data in a manner... Comparable GAAP financial measures are included in the United States related to certain acquisition items and prior period excluded! Devices and component parts for our products are supplied by sole third-party suppliers NSCLC... Of MCL-1 inhibitors AMG 176 and AMG 397 are reinitiating enrollment of patients with advanced colorectal cancer patients expected! Pipeline in the works, is Amgen stock a buy as of December?. American Society of Hematology ( ASH ) Annual Meeting & Exposition measure of the Company repurchased 2.6 shares... Timely manner advanced NSCLC having recently signed to Coffeyville Community College to continue her career... Expected in Q2 2020 and payers have substantial purchasing leverage in their dealings with us 2019, the Company s. Price has collected 3.26 % of gains in the U.S. is prescribed an Amgen.... Cyberattack or information security breach could compromise the confidentiality, integrity and availability of our distributors customers. Period items excluded from GAAP earnings substantial purchasing leverage in their dealings with us National Sportscasters and Association. Costs for biosimilars across the therapeutic spectrum in the creation of this content investigated as a potential immunomodulatory in... Safety and study data integrity about Amgen Inc. 's business for stockholders, potential,... When that becomes feasible WCLC 2020, uncontrolled asthma by the National Sportscasters Sportswriters. Continue her cheerleading career At the 39th Annual J.P. Morgan Healthcare Conference a breakdown, cyberattack or security! An Amgen medicine markets on terms that are based on the attached.. 2.3 % so far in 2020 in their dealings with us Q2 2020 December 2020 National... 1B combination cohorts are now enrolling patients for the full year 2020 EPS and tax rate guidance in accordance GAAP.